Category: Amlan In the News

press release, varium® patent announcement

OIL-DRI ANNOUNCES ISSUANCE OF U.S. PATENT FOR MINERAL-BASED TECHNOLOGY FOR USE IN ANTIBIOTIC-FREE ANIMAL PROTEIN PRODUCTION

Posted on | by Reagan Culbertson

FOR IMMEDIATE RELEASE – July 2, 2020

CHICAGO—July 2, 2020— Oil-Dri Corporation of America (NYSE: ODC), a leading manufacturer of sorbent minerals, parent company to Amlan International, today announced that the United States Patent and Trademark Office has issued U.S. Patent 10,568,903 entitled “Clay Product and Uses Thereof.” The patent covers two existing commercial products, Varium® for poultry and NeoPrime™ for swine, that are helping global animal protein producers thrive in an era of antibiotic-free production.

This patent provides a methodology for using a natural, mineral-based formula to mitigate the effects of exposure to pathogenic bacteria and the disease-causing toxins they produce, which damage gut health and function. Advancements in natural feed additives are helping to transform animal protein production by providing proven and reliable alternatives to in-feed antibiotics used to promote growth and productivity.

“The United States is the second country to issue a patent for this mineral-based technology and it validates the important role that minerals play in disrupting the cycle of intestinal disease,” said Daniel S. Jaffee, President and CEO of Oil-Dri Corporation of America. “When using Varium, for example, poultry integrators have eliminated the use of in-feed antibiotics to promote growth while maintaining production efficiencies and profitability. Our customers report they are growing healthier birds that are less stressed and have increased the marketability of their products through improved skin, liver and feet quality.”

“The market opportunity for natural alternatives to antibiotics is large and growing,” says Flemming L. Mahs, President of Amlan International, a Nevada corporation. “Market data indicates that within medicinal feed additives, anti-infectives are a $2.4 billion global market and usage has been declining as a result of changing consumer sentiment towards the use of antibiotics and regulatory restrictions limiting the use of antibiotics in animal protein production. Intestinal disease costs the global livestock industry more than $6 billion annually in economic loss and costs are rising as sub-therapeutic antibiotic use declines.”

Mineral-Based Technology

Unlike antibiotics, which are designed to kill bacteria, the patented technology includes a synergistic formula of three ingredients with distinct modes of action: (1) a surface-activated mineral that facilitates chemical binding of pathogenic intestinal bacteria and the disease-causing toxins they produce; (2) an immunomodulator that stimulates an animal’s innate immune system to naturally defend against disease; and (3) an energy source for the replenishment of intestinal epithelial cells that is essential for healthy gut function. Upon inclusion of this patented technology in animal feed, current producers have effectively eliminated the use of antibiotics to promote growth and have experienced equivalent or better outcomes.

Amlan International

Oil-Dri Corporation of America (NYSE: ODC), a Delaware corporation doing business as “Amlan International,” is a global leader in proven solutions that improve the intestinal health and productivity of livestock. Amlan has grown its product offering across the intestinal health and AGP-alternative market, driven largely by the research conducted at its laboratory campus in Vernon Hills, Illinois.

Amlan International sells animal health products outside of the United States. Product associated claims do not constitute medical claims and may differ based on government requirements. Product availability may vary by country.

###

MEDIA CONTACT
Reagan Culbertson
press@amlan.com

Share this post:

Facebooktwittergoogle_plusredditpinterestlinkedinmail

Follow us:

Facebooktwittergoogle_pluslinkedinrssyoutube

Dr. Hongyu Xue's Presentation at the 3rd ATA

In vitro and in vivo evaluation of therapeutic effects of Neutrapath against Salmonella Typhimurium

Posted on | by Marissa Magee

H. Xue1*, D. Wang1, B.M. Hargis2; & G. Tellez2

1Amlan International, Chicago, IL, 60061, USA
2Department of Poultry Science, University of Arkansas, Fayetteville AR 72701, USA
*E-mail: Hongyu.Xue@Amlan.com

Source: The 3rd International Symposium on Alternatives to Antibiotics (ATA)

Antibiotic resistance in foodborne pathogens such as Salmonella is a major concern for public health safety. The poultry industry is compelled to seek alternative solutions to antibiotics in reducing the incidence of Salmonella colonization in broiler chickens at the farm level. NeutraPath is a formulated feed additive that features a proprietary blend of essential oils, medium-chain fatty acids and an activated toxin-adsorbing mineral. This formula has been shown to neutralize a variety of key virulence factors of pathogenic bacteria in addition to exerting direct bacteriostatic/bacteriocidal effects. This study was aimed to evaluate in vitro and in vivo effects of NeutraPath on Salmonella enterica sv. Typhimurium (ST) infection in broiler chickens.

An in vitro digestion model was used to simulate three gastrointestinal compartments with physiologically relevant pH and enzymatic conditions correspondent to that of crop, proventriculus and intestinal section respectively. In the in vivo trial, one-day old male broiler chicks were randomly allocated to one of three groups (n=30 chickens), i.e., Challenged control with non-treated feed and NeutraPath supplemented at 0.25% and 0.5% in feed. Chickens were orally gavaged with 106 CFU of live ST per chicken at 9-d old. Twenty-four hours post challenge, ceca-cecal tonsils were removed to evaluate Salmonella recovery and serum was collected for FITC-d determination. Differences between treatments were analyzed using one-way ANOVA.

In the in vitro trial, 0.25% NeutraPath significantly reduced total CFU of ST recovered in the proventriculus and intestinal compartments compared with control (P<0.05). NeutraPath treatment at 0.25% and 0.5% resulted in a 41.7% and 33.3% reduction in the prevalence of ST in ceca respectively compared to the challenged control (P<0.05 for both comparisons). Both dose levels also significantly reduced total ST CFU recovered in the ceca by 1.84 and 1.79 Log10 CFU/g compared to the challenged control (P<0.05 for both comparisons). Further, NeutraPath at both doses significantly reduced serum FITC-dextran levels (P<0.05).

Based on these in vitro and in vivo data, the NeutraPath treatment had the therapeutic potential to reduce ST colonization in broiler chickens and preserve the functional integrity of the intestinal barrier of chickens during ST challenge.

Share this post:

Facebooktwittergoogle_plusredditpinterestlinkedinmail

Follow us:

Facebooktwittergoogle_pluslinkedinrssyoutube

Efficiently raising antibiotic-free broilers

Posted on | by Marissa Magee

Broiler growers worldwide are under pressure to reduce or eliminate growth-promoting antibiotics from bird diets. Promoting intestinal health through improved nutrition and immune system stimulation can help producers successfully replace or reduce antimicrobials without sacrificing bird health or performance.

Source: All About Feed (https://www.allaboutfeed.net/Specials/Articles/2019/12/Efficiently-raising-antibiotic-free-broilers-511753E/), Antibiotic Reduction Special Edition, Dec 2019

BY DR HONGYU XUE, LIFE SCIENCES DIRECTOR, AMLAN INTERNATIONAL

Completely removing or significantly reducing the use of antibiotic growth promoters (AGPs) raises many issues for broiler producers. Their foremost concerns are whether their grow-out operations can remain competitive, profitable and free from performance-robbing intestinal diseases like necrotic enteritis.

Broiler growers moving to antibiotic-free poultry production now have the advantage of hindsight, unlike those who were impacted by the first antibiotic bans of 20-plus years ago.

Since then, many compounds have been studied for their ability to replace AGPs. Prebiotics, probiotics, enzymes, organ- ic acids, minerals and other additives can be used successfully to manage gut health instead of AGPs. But, and this is a big ca- veat, these products are often used in combination and in- crease feed costs. Formulated feed additives that combine the right ingredients to replace one or more other additives and help birds grow efficiently may be just what today’s broiler producers need. Certain formulated feed additives are de- signed to use different and (ideally) synergistic modes of ac- tion to achieve desired responses. Such products are typically tested by a team of specialists to determine the optimal for- mulation so growers don’t have to experiment. Those factors help formulated products deliver value.

Intestinal health is critical

A healthy gut is essential to a healthy bird. However, the gastrointestinal (GI) tract is the site of substantial disease challenges, including pathogens like Clostridium perfringens, Escherichia coli and Salmonella spp. An effective antibiotic alternative should demonstrate activity in three areas:

  1. The intestinal lumen to reduce bacterial disease challenges,
  2. The intestinal epithelium to strengthen the intestinal barrier,
  3. The gut-associated lymphoid tissue (GALT) to stimulate immune function.

Varium is used worldwide in antibiotic-free poultry production to achieve equivalent outcomes as AGPs, often replacing one or more additional feed additives being used as replacements to AGPs. Multiple controlled studies and field trials demon- strate that Varium, a proprietary formulated feed additive, can replace some or all AGPs use in broiler diets. The components of the all-natural product work synergistically to provide a multifaceted approach to supporting intestinal health and im- munity, promoting efficient feed use and improving overall flock performance, see Figure 1. Those mechanisms of action support bird intestinal health and efficiency by:

  1. Reducing total biotoxin load, which helps protect intestinal homeostasis,
  2. Reducing pathogen load through type-1 fimbriae bacterial adhesion,
  3. Providing enterocytes with a preferred energy source, which enhances the intestinal barrier,
  4. Stimulating the innate and adaptive immune responses to help birds defend against pathogens.

Trials find comparable performance

For broiler producers seeking evidence-based options, pre- adoption trial data from commercial broiler producers in Brazil demonstrate how Varium performs alone or in combi- nation with other feed additives. In a 40-day feeding trial conducted under natural challenge, 2,400 day-old chicks were assigned to one of four treatments (Table 1).

In addition to the specified treatments, all diets included common anti- coccidial treatments. Captured and calculated data included body weight, feed intake, mortality, feed conversion ratio (FCR) and percent mortality. Broilers fed diets containing Varium alone or in combination with other additives had weight gain and FCR comparable to those fed a diet contain- ing two antibiotics, a mycotoxin binder and a probiotic. No significant differences in day-40 weight gain or FCR were de- tected among treatments. However, mortality at day 40 was substantially lower for broilers consuming Varium in their di- ets. Broilers fed diets containing Varium had higher produc- tion efficiency indices (PEI) than the control group. A second trial in Brazil compared the performance of Varium to Tylosin when fed to birds at a commercial broiler grow-out operation that produced about 170,000 birds per day for slaughter. Tylosin at a rate of 55 ppm was added to diets between August 2017 and July 2018. Tylosin and a an enzyme-based mycotox- in deactivator were then removed and Varium was added at a rate of 0.1% from August 2018 through July 2019.

Captured and calculated data included body weight and age at slaughter, average daily gain, FCR, PEI, mortality and liver quality. No significant differences were detected between treatments for FCR, average daily gain, average body weight, average age at slaughter, PEI or percent mortality. Interesting- ly, faeces from broilers fed diets containing the feed additive were firmer, resulting in better quality litter than those birds receiving Tylosin in their diets, see Table 2. Better litter quality means decreased incidence of foot pad dermatitis.

Table 1 – Trial results under natural challenge.
Treatments investigated in a 40-day feeding trial with natural challenge
Treatment Additives
ControlHalquinol + virginiamycin + mycotoxin binder + Bacillus subtilis
Va + HVarium + halquinol + mycotoxin binder + B. subtilis
Va + VirVarium + virginiamycin + mycotoxin binder + B. subtilis
VariumVarium (1 kg/MT)
Table 2 – Averages of key performance parameters.
Treatment Body weight
(kg) 		Age (d) Daily gain
(g) 		FCR PEI Mortality
(%) 		Liver quality
(%)

Tylosin + mycotoxin binder 		3.070 45.6 67.3 1.68 388 3.80 1.48
Varium 3.041 44.6 68.0 1.63 401 3.84 1.54

Profitable antibiotic-free production

Intestinal health becomes more important to profitable broiler production as AGPs are removed from bird diets. But it takes the right combination of feed ingredients and additives along with many other factors. Varium is helping commercial producers save money by replacing one or more feed addi- tives in broiler diets while maintaining or improving feed conversion and weight gain and decreasing mortality. Efficient broiler production without AGPs is possible.

Share this post:

Facebooktwittergoogle_plusredditpinterestlinkedinmail

Follow us:

Facebooktwittergoogle_pluslinkedinrssyoutube

Clare Mari Torralba

Clare Mari Torralba Joins Amlan as Regional Sales Director – APEC

Posted on | by Marissa Magee

CHICAGO, March 19, 2019 — Amlan International, a global leader in the development of innovative products that improve intestinal health and productivity for livestock, announces the addition of Ms. Clare Mari Torralba as Regional Sales Director for the Asia-Pacific region (APEC). In her new role, Ms. Torralba will plan and execute Amlan’s sales strategy and manage the regional sales team to deliver products and services that ensure long-term customer value and profitability.

Ms.Torralba brings extensive sales leadership in the feed additive industry to Amlan. Her experience includes serving as Sales Manager, Regional Vice President and most recently as Head of Global Business for Evonik Industries. Her proven professional expertise is in P&L management of multi-cultural businesses.

“We are extremely proud to welcome Ms. Torralba to the Amlan/Oil-Dri family,” said Flemming L. Mahs, President of Amlan International, a Nevada corporation. “Her elevated knowledge of sales, management and animal health makes her an ideal addition to the team.”

“I am thrilled to be a part of the growing team of accomplished animal health professionals,” Torralba said. “I look forward to building an empowered, customer-focused sales organization and driving the business of Amlan International to even greater levels of success.”

For more information about Amlan’s product portfolio, visit bioinsightsaml.wpengine.com.

###

MEDIA CONTACT
Reagan Culbertson
(312) 706-3256
reagan.culbertson@amlan.com

ABOUT AMLAN INTERNATIONAL

Oil-Dri Corporation of America (NYSE: ODC), a Delaware corporation doing business as “Amlan International,” has grown its product offering across the intestinal health and AGP-alternative market, driven largely by the research conducted at its laboratory campus in Vernon Hills, Illinois. In 2017, the company added the Richard M. Jaffee Laboratory for Applied Microbiology to the campus. In 2013, the company’s global reach expanded with the establishment of its China subsidiary in Shenzhen.

Amlan International sells animal health products outside of the United States. Product-associated claims may differ based on government requirements and product availability may vary by country.

Source: Global News Wire

Share this post:

Facebooktwittergoogle_plusredditpinterestlinkedinmail

Follow us:

Facebooktwittergoogle_pluslinkedinrssyoutube

Disarming the Bacterial Enemy

Posted on | by Chris Underdown

Disarming the Bacterial Enemy Offers a New Approach to Enteric Infection Control

Leading researchers shared their insights into antivirulence therapy, a new approach for controlling livestock enteric infections, during an Amlan sponsored symposium.

Source: O Presente Rural, EDIÇÃO DE QUARTA-FEIRA , 13 DE FEVEREIRO DE 2019

Access to novel therapies that control diseases caused by antibiotic-resistant bacteria is a major challenge facing veterinary professionals and livestock producers. One emerging alternative approach to controlling intestinal diseases caused by bacteria appears particularly promising: antivirulence therapy.

Poultry professionals from industry and academia recently had the opportunity to learn about this new approach to fighting bacterial diseases such as necrotic enteritis caused by Clostridium perfringens and the research investigations supporting it. Amlan International, a leader in developing advanced solutions that enhance intestinal health and productivity in livestock, hosted leading experts in antivirulence therapy during a special symposium at the 2018 Poultry Science Association’s Latin American Scientific Conference in Sao Paulo, Brazil.

“An antivirulence approach to controlling and even preventing bacterial diseases is a significant paradigm shift in the post-antibiotic-growth-promoter era,” said Hongyu Xue, MD, PhD, Director of Life Sciences for Amlan International. “The symposium highlighted the significance of this new concept and was designed to increase awareness for the topic among animal health practitioners, which it did.”

What is antivirulence therapy?

Tom Defoirdt, PhD, a leading microbiology researcher with the University of Ghent and one of the symposium speakers, explained that bacteria produce or express a variety of molecules, known as virulence factors, which help them colonize the host animal’s gut and damage the intestinal epithelial cells. These factors range from fiber-like structures that enable bacterial attachment to host cells to toxins that can inhibit protein synthesis, damage cell membranes or activate immune responses. These virulence factors are essential for infection to occur. But if bacteria are prevented from producing virulence factors or the expressed factors are neutralized, the bacteria cannot cause infection. Consequently, antivirulence therapies offer an important alternative strategy for controlling bacterial diseases.

Dion Lepp, PhD, a biologist with the Agriculture and Agri-Food Canada, Guelph Research and Development Center, and symposium speaker told attendees that unlike traditional antibiotics which kill or inhibit bacteria and can lead to drug resistance, antivirulence therapies interfere with bacterial virulence mechanisms without placing selective pressures that are associated with traditional antibiotics. For a number of disease-causing bacteria, quorum sensing plays a key role in regulating virulence and therefore offers a potential intervention point for antivirulence therapies.

An economic and disease challenge for poultry producers

For decades, growth-promoting antibiotics have been routinely used in commercial poultry feed to control necrotic enteritis caused by C. perfringens and ensure bird performance. However, in those countries where antibiotic growth promoters have been reduced or phased out, necrotic enteritis has reemerged as a significant problem. On average, necrotic enteritis is estimated to cost producers US$0.05 to US$0.063 per bird.

Technology that leverages an antivirulence approach to minimizing enteric disease is available to poultry producers now. Dr. Xue shared findings from recent studies conducted at Amlan’s Innovation Center that showed a unique activated enterosorbent mineral, Calibrin®-Z, can adsorb and degrade chemical signals (i.e., quorum sensing molecules) used by bacteria to communicate with each other. Further, Amlan’s scientists generated multiple lines of evidence demonstrating this sorbent mineral can neutralize a diverse repertoire of secreted or surface-exposed virulence factors that compromise bird intestinal health and productivity.

“Often the key challenge is an inherent narrow spectrum of activity for the target bacteria,” Dr. Xue said. “But our adsorbent mineral has a broad spectrum of activity, so it can be used to target a large number of antivirulence factors. We’re really excited about the possibilities.”

At a time when poultry producers are looking for alternatives to antibiotics to help maintain the health of their flocks, feed additives that target bacterial virulence factors can be a valuable tool for promoting animal health. Livestock producers can look forward to new innovative products backed by research from Amlan International.

An example of antivirulence therapy in action. Bacteria release autoinducers (quorum sensing signal molecules) into their immediate environment to monitor changes in population density and to “talk” to each other during quorum sensing. Calibrin-Z, a unique activated mineral available from Amlan International, has been shown to adsorb and degrade these signal molecules, disrupting quorum sensing and, ultimately, bacterial virulence

Click Here to read the story in Portuguese

Share this post:

Facebooktwittergoogle_plusredditpinterestlinkedinmail

Follow us:

Facebooktwittergoogle_pluslinkedinrssyoutube

Amlan to present emerging alternative to antibiotics in poultry disease management at WVPA Asia meeting

Posted on | by ideamktg

Dr. Maximillian Sim of Amlan International to present at global poultry veterinary conference on October 1, 2018

CHICAGO – SEPTEMBER 10, 2018 – Maximillian Sim, DVM, Commercial and Technical Consultant for Amlan International, will present research on bacterial quorum quenching as a valuable alternative to bactericidal treatments in managing poultry disease at the World Veterinary Poultry Association (WVPA) Asia Meeting in Kuala Lumpur, Malaysia, on October 1-2, 2018.

Dr. Sim has 13 years of experience working in the animal health industry, providing field technical services and market development of nutraceutical products in Asia. His presentation, “Disrupting Bacterial Quorum Sensing as an Emerging Alternative to Antibiotics – Human and Animal Applications,” will take place at 1 p.m. on Monday, October 1, at the conference location at the Pullman KLCC Hotel in Kuala Lumpur.

“To meet increasing global demands for animal protein, producers and nutritionists require viable alternatives to antibiotic growth promoters (AGPs) to maintain intestinal health and improve performance in their flocks,” says Flemming Mahs, President of Amlan International, a Nevada corporation. “Recent research in quorum sensing is showing that our unique activated mineral technology provides benefits to producers in ways previously thought to be unimaginable.”

Quorum sensing is a signaling system used by intestinal bacteria to communicate with each other and monitor cell population density. Dr. Sim will present new research that demonstrates the performance of Amlan’s activated mineral technology in adsorbing and degrading — or “quenching” — quorum sensing signal molecules. The activated mineral technology is one of the functional ingredients in VariumTM an intestinal health product that supports growth in poultry. Its anti-virulent attributes neutralize quorum sensing signal molecules to reduce
the harmful effects of pathogenic bacteria.

“The research that Dr. Sim will present at WVPA is exciting for the industry,” Mahs says. “An in-depth understanding of host-pathogen interaction and anti-virulence strategies such as quorum quenching hold great promise for minimizing the effects of bacterial disease in poultry.”

Note to media: For an interview with Dr. Sim, contact Reagan Culbertson at reagan.culbertson@amlan.com. For more information about Amlan’s portfolio of intestinal health products, visit Amlan.com.

About Amlan International

Oil-Dri Corporation of America (NYSE: ODC), a Delaware corporation doing business as “Amlan International,” has grown its product offering across the intestinal health and AGP-alternative market, driven largely by the research conducted at its laboratory campus in Vernon Hills, Illinois. In 2017, the company added the Richard M. Jaffee Laboratory for Applied Microbiology to the campus. In 2013, the company’s global reach expanded with the establishment of its China subsidiary in Shenzhen. Further information on Amlan International is available at Amlan.com.

Amlan International sells animal health products outside of the United States. Product-associated claims may differ based on government requirements and product availability may vary by country.

Share this post:

Facebooktwittergoogle_plusredditpinterestlinkedinmail

Follow us:

Facebooktwittergoogle_pluslinkedinrssyoutube

“We are polluting the environment with resistant genes”

Posted on | by Chris Underdown

“We are polluting the environment with resistant genes”

Source: AllAboutFeed.net, 17 Aug 2018

By: Emmy Koeleman, Editor: All About Feed & Dairy Global

Antimicrobial resistance is not new, but actually a very old phenomenon. But we see the amount of resistant bacteria genes in the soil increasing, which is more worrisome than antibiotics use on its own.

This is according to microbiologist Dr Margie Lee, professor and head of the Department of Biomedical Sciences and Pathobiology in the Virginia-Maryland College of Veterinary Medicine at Virginia Tech in the US. Dr Lee presented her insights on antimicrobial resistance at the first-annual summer international poultry symposium, organised by Amlan International (Aug 2-3 in Chicago, US).

Click Here to read the full story.

Share this post:

Facebooktwittergoogle_plusredditpinterestlinkedinmail

Follow us:

Facebooktwittergoogle_pluslinkedinrssyoutube

Amlan’s First Summer International Poultry Seminar Brings Solutions for Next Generation Productivity

Posted on | by Chris Underdown

CHICAGO — August 17, 2018 — To learn more about next generation AGP-alternatives, poultry producers from around the world attended Amlan’s First Summer International Poultry Seminar Aug. 2–3 in Chicago. Attendees heard from industry-thought-leaders about the latest research into the impact of bacterial resistance on modern poultry operations and what measures are needed to drive progress in global poultry production.

Producers worldwide lose $6 billion annually due to bacterial-related disease in their flocks. The reduction and elimination of antibiotic growth promoters (AGPs) in poultry diets is leading to a higher incidence of diseases that challenge gut health, making those economic losses worse. The two-day event hosted by Amlan International, a global leader in the development of innovative products that improve intestinal health and productivity in livestock, attracted producers from 13 countries for a unique learning experience and a chance to exchange ideas about poultry disease management.

“We hosted experts on the forefront of academic research and producers on the leading edge of animal husbandry practices for a deep look into barriers to optimal intestinal health, productivity and profitability in poultry production,” said Flemming Mahs, President, Amlan International. “Even more exciting was to see the new technologies that are addressing some of these challenges. It is this new innovation that promises strategic progress for poultry producers and can provide benefits throughout the food chain.”

Seminar presenters included leading poultry producers such as Amick Farms (OSI Group), which produces 3 million chickens per week and Tyson Foods, one of the largest companies in the global food industry. Leading academic researchers included Dr. Margie Lee, Department Biomedical Sciences and Pathobiology, Virginia Tech University; Dr. John Maurer, College of Veterinary Medicine, University of Georgia; Dr. Peter Ferket, Department of Poultry Science, North Carolina State University; and Dr. Marvin Whiteley, Biological Sciences, Georgia Tech.

Successful AGP-Free Production

Steve Kernen, Vice President of Marketing for Amick Farms, said that for the industry, “antibiotic-free poultry production is like a freight train. You can choose to get on board, or not get on board.” U.S-based companies such as Amick Farms and Tyson Foods are converting some or all of their production to antibiotic-free, but the change comes at a cost.

Those costs, according to Dr. Lee of Virginia Tech University, include reduced efficiency and increased production costs. Producers such as Tyson Foods are overcoming those challenges by refining nutrition management, adopting new technology and altering animal husbandry practices.

“In no-antibiotics-ever (NAE) production systems, maintaining gut health in the birds and minimizing intestinal disruptions are critically important,” said Dr. Phillip Smith, Tyson Senior Poultry Nutritionist. “Having a strong nutritional program is even more important in NAE. Some of the new nutrition technologies that are coming forward are very promising to help address these challenges.”

Advancements in natural feed additives are helping to transform the poultry industry by providing proven and reliable alternatives to antibiotic growth promoters for efficient feed use and improved bird performance. At the seminar, field results from Amlan’s natural growth promotion product VariumTM were presented that demonstrated the product’s effectiveness at improving growth and reducing mortality. Varium works by supporting the bird’s intestinal health and immune system and by controlling fungal and bacterial diseases caused by Clostridium perfringens, Salmonella and E. coli.

Mahs added, “It’s an exciting time in the livestock health industry because, while the global challenges are great, the opportunities to create the necessary solutions are even greater. At Amlan, we use research to create innovative products with proven efficacy to solve global challenges across livestock production.”

For more information, visit bioinsightsaml.wpengine.com.

###

MEDIA CONTACT
Reagan Culbertson
(312) 706-3256
reagan.culbertson@amlan.com

ABOUT AMLAN INTERNATIONAL

Oil-Dri Corporation of America (NYSE: ODC), a Delaware corporation and doing business as “Amlan International,” has grown its product offering across the intestinal health and AGP-alternative market, driven largely by the research conducted in its laboratory campus in Vernon Hills, IL. In 2013, the company’s global reach expanded with the establishment of its China subsidiary in Shenzhen. Further information on Amlan International is available at bioinsightsaml.wpengine.com.

Source: Global News Wire

Share this post:

Facebooktwittergoogle_plusredditpinterestlinkedinmail

Follow us:

Facebooktwittergoogle_pluslinkedinrssyoutube

Don’t Kill, But Tame the Bacteria

Posted on | by Chris Underdown

Don’t kill, but tame the bacteria

Source: AllAboutFeed.net, 13 Aug 2018

By: Emmy Koeleman, Editor: All About Feed & Dairy Global

Producing broiler meat with the label ‘no antibiotics ever’ is becoming a common thing in the US. In the meantime, the poultry sector fears that this leads to a less efficient system, in which it is harder to control major poultry diseases. Luckily, a new set of savvy feed additives that keep bad bacteria under control is on its way.

Poultry production under the philosophy ‘no antibiotics ever’ (NAE), is spreading like a wild fire in the US and also in some other parts of the world. Although this sounds like a good development, and it is, it also comes with challenges, both from a nutritional standpoint as well as keeping the margins and being able to sell the products. At a recent first-annual summer international poultry symposium, organised by Amlan International, the challenges and solutions for poultry producers to produce under antibiotic free systems were discussed in further detail.

Click Here to read the full story.

Share this post:

Facebooktwittergoogle_plusredditpinterestlinkedinmail

Follow us:

Facebooktwittergoogle_pluslinkedinrssyoutube